BIOLIFE SOLUTIONS INC (BLFS) Q3 2025 10-Q Quarterly Report
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Electromedical & Electrotherapeutic ApparatusSEC EDGAR BIOLIFE SOLUTIONS INC (BLFS) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
BIOLIFE SOLUTIONS INC Q3 2025 10-Q Analysis
Risk Factors
- • New accounting standards ASU 2025-07, ASU 2025-06, ASU 2025-05, ASU 2025-04, ASU 2025-03 issued by FASB, effective 2026-2028, no expected material impact stated
- • Material update: April 2025 acquisition of PanTHERA, $15.5M in-process R&D cost expensed immediately due to no alternative future use
- • Regulatory/legal risk: $5.4M total loss contingencies for Global Cooling lawsuits, deemed probable to settle next fiscal year, covered by insurance minus deductibles
- • Operational/market risk: Divestiture of Freezer Business segments in 2024, including Global Cooling, SciSafe, and CBS, with divestiture losses totaling $8.9M (Global Cooling), gain $28.1M (SciSafe), loss $3.4M (CBS)
- • Financial risk: $7.2M earnout liability contingent on PanTHERA revenue and milestones, probability assessed as remote, so no earnout recognized as of 9/30/25
Get deeper insights on BIOLIFE SOLUTIONS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.